TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Core Insights - TG Therapeutics reported significant growth in 2024, with BRIUMVI U.S. net revenue reaching $103.6 million in Q4 and$310 million for the full year, marking approximately 250% year-over-year growth [7][10] - The company anticipates total global revenue of approximately $540 million for 2025, including U.S. net product revenue of about$525 million [6][10] - The CEO highlighted strong adoption of BRIUMVI for relapsing forms of multiple sclerosis (RMS) and progress in patent protection and clinical trials [2][6] Financial Performance - For Q4 2024, total revenue was approximately $108.2 million, compared to$44.0 million in Q4 2023, while full-year revenue was $329.0 million, up from$233.7 million in 2023 [43] - The net income for Q4 2024 was $23.3 million, a significant improvement from a net loss of$14.4 million in Q4 2023 [43] - Cash, cash equivalents, and investment securities totaled $311.0 million as of December 31, 2024, up from$217.5 million a year earlier [45] Product Development and Pipeline - BRIUMVI has been launched in Europe and is now available in several additional countries [7] - The company has strengthened its patent portfolio for BRIUMVI, extending protection through 2042 [7] - Ongoing clinical trials include a Phase 1 trial for subcutaneous ublituximab and a pivotal program based on data from the ENHANCE trial [7][11] Market Position and Strategy - BRIUMVI is indicated for the treatment of adults with RMS in the U.S., EU, and UK, with a focus on enhancing patient experience and expanding market reach [14][15] - The company has entered into a global license agreement with Precision BioSciences for the development of CAR T therapy for autoimmune disorders [7] - TG Therapeutics aims to present updated data at major medical conferences throughout the year to bolster its market presence [11]